|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
|
23845441 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
|
22180495 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAF as a target for cancer therapy.
|
21426297 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
|
20857202 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.
|
24594804 |
2014 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Clinical biomarkers in oncology: focus on colorectal cancer.
|
19537845 |
2009 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
23549875 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
|
22448344 |
2012 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
|
19213871 |
2009 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
In addition, a significant association between mismatch-repair (MMR) deficiency and the V599E mutation in colorectal tumors has been found.
|
14654916 |
2004 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
|
21163703 |
2011 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
|
20413299 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
23325582 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
|
25989278 |
2015 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
|
24163374 |
2014 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600E-mutant colorectal tumors.
|
24107445 |
2013 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Our results support the use of VE1 IHC for identification of colorectal neoplasms harboring the BRAF V600E mutation.
|
25517872 |
2015 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
|
20350999 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
CausalMutation
|
CLINVAR |
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
|
21129611 |
2010 |
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Rac1b overexpression and B-Raf(V600E) are significantly associated in primary colorectal tumors (P = .008) and colorectal cell lines.
|
18602919 |
2008 |